Concepedia

Author

Joachim R. Kalden

Friedrich-Alexander-Universität Erlangen-Nürnberg

Also Known As

J Kalden, J R KALDEN, J R Kalden, J. Kalden, J. R. KALDEN, J. R. Kalden, J.R Kalden, J.R. KALDEN, J.R. Kalden, JOACHIM R. KALDEN

221

Publications

19K

Citations

51

H-Index

100

Concepts

All Affiliations

Friedrich-Alexander-Universität Erlangen-NürnbergUniversitätsklinikum ErlangenLeiden UniversityMedical University of ViennaCharité - Universitätsmedizin Berlin
JR

About

Joachim R. Kalden is an author at Friedrich-Alexander-Universität Erlangen-Nürnberg specializing in medicine, immunology, and autoimmune disease.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

27

39

7.1K

2

Allergy

10

10

833

3

Biochemistry

2

2

108

4

Health Sciences

1

1

17

5

Natural Sciences

1

1

44

Joachim R. Kalden

×

91

Publications

17.2K

Citations

44

H-Index

YearCitations

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

Lars Klareskog, Désirée van der Heijde, J Jäger,

The Lancet

2004

1.8K

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

Michael J. Elliott, Ravinder N. Maini, Marc Feldmann,

The Lancet

1994

1.7K

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

Ravinder N. Maini, Ferdinand C. Breedveld, Joachim R. Kalden,

Arthritis & Rheumatism

1998

1.6K

Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European community

Claudio Vitali, Stefano Bombardieri, Haralampos Μ. Moutsopoulos,

Arthritis & Rheumatism

1993

1.4K

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial

E. William St. Clair, Désirée van der Heijde, Josef S Smolen,

Arthritis & Rheumatism

2004

1.2K

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

Josef S Smolen, FC Breedveld, Michael Schiff,

Lara D. Veeken

2003

1K

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial

Josef S Smolen, Joachim R. Kalden, David L. Scott,

The Lancet

1999

769

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Daniel E. Fürst, Edward Keystone, Jürgen Braun,

Annals of the Rheumatic Diseases

2011

691

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

Christian Antoni, Arthur Kavanaugh, Bruce Kirkham,

Arthritis & Rheumatism

2005

636

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

P. Charles, M. J. Elliott, Diana Davis,

PubMed

1999

533

Page 1